Two cases of Amyloid-Related Imaging Abnormalities (ARIA) following lecanemab treatment for alzheimer's disease and a literature review.

OBJECTIVE

To investigate the imaging characteristics and management strategies of amyloid-related imaging abnormalities (ARIA) in Alzheimer's disease (AD) patients treated with lecanemab.

METHODS

We report two clinical cases of ARIA following lecanemab treatment and analyze the imaging features, risk factors, and management strategies of ARIA based on the latest literature.

RESULTS

The occurrence of ARIA is associated with risk factors such as advanced age, ApoE ε4 carrier status, cerebral amyloid angiopathy (CAA), and a history of cerebrovascular disease.

CONCLUSION

During lecanemab treatment for AD, it is essential to fully understand the mechanisms, imaging characteristics, and management strategies of ARIA. Close monitoring of clinical symptoms and imaging changes is crucial for the timely detection and appropriate management of ARIA.